Surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma.
Mortensen, Mette S; Bandak, Mikkel; Kier, Maria G G; Lauritsen, Jakob; Agerbaek, Mads; Holm, Niels V; von der Maase, Hans; Daugaard, Gedske.
; 123(7): 1212-1218, 2017 04 01.
Artigo em Inglês | MEDLINE | ID: mdl-27893934
Markedly increased incidence and improved survival of testicular cancer in the Netherlands.
Risk factors for loss to follow-up during active surveillance of patients with Stage I seminoma.
A Population-Based Analysis of Incidence, Mortality, and Survival in Testicular Cancer Patients in Lithuania.
Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma.
Outcomes in stage I testicular seminoma: a population-based study of 9193 patients.
Radiotherapy for stage I seminoma of the testis: Organ equivalent dose to partially in-field structures and second cancer risk estimates on the basis of a mechanistic, bell-shaped, and plateau model.
Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma.
Robot-assisted post-chemotherapy retroperitoneal lymph node dissection in germ cell tumor: is the single-docking with lateral approach relevant?
Testicular cancer in Europe and the USA: survival still rising among older patients.
Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA).